sars-cov-2 positive patients on a ventilator. patients with any open wounds, injuries, inflammation, erythema, or infection (other than covid-19) affecting the nasal passages, nose, upper lip, and the area of skin around the nose, including herpes simplex lesions. patients with a history of abnormal bleeding, bruising, frequent nosebleeds, or those diagnosed with von willebrand disease. patients with nasal polyps or significant anatomical nasal abnormalities. patients with a history of nasal surgery, including cauterization, in the last 6 months. patients who currently have or have ever had a nose or septum piercing patients treated with antiviral medications in the past 7 days known allergy or history of significant adverse reactions to benzalkonium chloride or related compounds, or to any of the excipients. known or suspected pregnancy, pregnancy planned during the study period, or breastfeeding. clinically significant mental illness (to be determined by the investigator) recent history of (last 12 months) or strong potential for alcohol or substance abuse. alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz of beer, 5.0 oz of wine, or 1.5 oz of distilled spirits) exposure to any agents being researched within 30 days prior to admission to the study. prior enrollment in this study if the patient has a condition that the investigator believes would interfere with their ability to give informed consent or comply with study instructions, or that could confuse the interpretation of study results or put the patient at undue risk.

sars-cov-2 positive patients on a ventilator. patients with any open wounds, injuries, inflammation, erythema, or infection (other than covid-19) affecting the nasal passages, nose, upper lip, and the area of skin around the nose, including herpes simplex lesions. patients with a history of abnormal bleeding, bruising, frequent nosebleeds, or those diagnosed with von willebrand disease. patients with nasal polyps or significant anatomical nasal abnormalities. patients with a history of nasal surgery, including cauterization, in the last 6 months. patients who currently have or have ever had a nose or septum piercing patients treated with antiviral medications in the past 7 days known allergy or history of significant adverse reactions to benzalkonium chloride or related compounds, or to any of the excipients. known or suspected pregnancy, pregnancy planned during the study period, or breastfeeding. clinically significant mental illness (to be determined by the investigator) recent history of (last 12 months) or strong potential for alcohol or substance abuse. alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz of beer, 5.0 oz of wine, or 1.5 oz of distilled spirits) exposure to any agents being researched within 30 days prior to admission to the study. prior enrollment in this study if the patient has a condition that the investigator believes would interfere with their ability to give informed consent or comply with study instructions, or that could confuse the interpretation of study results or put the patient at undue risk.

1. sars-cov-2 positive patients on a ventilator. 2. patients with any open wounds, injuries, inflammation, erythema, or infection (other than covid-19) affecting the nasal passages, nose, upper lip, and the area of skin around the nose, including herpes simplex lesions. 3. patients with a history of abnormal bleeding, bruising, frequent nosebleeds, or those diagnosed with von willebrand disease. 4. patients with nasal polyps or significant anatomical nasal abnormalities. 5. patients with a history of nasal surgery, including cauterization, in the last 6 months. 6. patients who currently have or have ever had a nose or septum piercing 7. patients treated with antiviral medications in the past 7 days 8. known allergy or history of significant adverse reactions to benzalkonium chloride or related compounds, or to any of the excipients. 9. known or suspected pregnancy, pregnancy planned during the study period, or breastfeeding. 10. clinically significant mental illness (to be determined by the investigator) 11. recent history of (last 12 months) or strong potential for alcohol or substance abuse. alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz of beer, 5.0 oz of wine, or 1.5 oz of distilled spirits) 12. exposure to any agents being researched within 30 days prior to admission to the study. 13. prior enrollment in this study 14. if the patient has a condition that the investigator believes would interfere with their ability to give informed consent or comply with study instructions, or that could confuse the interpretation of study results or put the patient at undue risk.

1. sars-cov-2 positive patients on a ventilator. 2. patients with any open wounds, injuries, inflammation, erythema, or infection (other than covid-19) affecting the nasal passages, nose, upper lip, and the area of skin around the nose, including herpes simplex lesions. 3. patients with a history of abnormal bleeding, bruising, frequent nosebleeds, or those diagnosed with von willebrand disease. 4. patients with nasal polyps or significant anatomical nasal abnormalities. 5. patients with a history of nasal surgery, including cauterization, in the last 6 months. 6. patients who currently have or have ever had a nose or septum piercing 7. patients treated with antiviral medications in the past 7 days 8. known allergy or history of significant adverse reactions to benzalkonium chloride or related compounds, or to any of the excipients. 9. known or suspected pregnancy, pregnancy planned during the study period, or breastfeeding. 10. clinically significant mental illness (to be determined by the investigator) 11. recent history of (last 12 months) or strong potential for alcohol or substance abuse. alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz of beer, 5.0 oz of wine, or 1.5 oz of distilled spirits) 12. exposure to any agents being researched within 30 days prior to admission to the study. 13. prior enrollment in this study 14. if the patient has a condition that the investigator believes would interfere with their ability to give informed consent or comply with study instructions, or that could confuse the interpretation of study results or put the patient at undue risk.